DeutschNewstral
Article
Fft.com on 2016-09-19 19:41
Sarepta shares surge 90% on FDA approval
Related news
- FSarepta shares surge 90% on FDA approvalft.com
- BSarepta Could Triple on Expedited FDA Approvalbarrons.com
Reporter sues FDA for documents related to Sarepta drug approvalbizjournals.com- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
- Shares of Cambridge biotech Sarepta crash after harsh FDA reviewbizjournals.com
Sarepta Shares Plunge as FDA Raises Doubts About Drugwsj.com- MGW Pharma shares surge on FDA briefing document that hints at approval of cannabis-derived drugmarketwatch.com
- MFlexion shares surge on FDA approval for its non-opioid knee pain medicationmarketwatch.com
- MMedicines Co. shares surge 2.5% on FDA approval of drug for complicated UTIsmarketwatch.com
- MFlexion shares surge 18% on news of FDA approval for non-opioid knee pain injectionmarketwatch.com
- MFDA advisers narrowly back accelerated approval of Sarepta gene therapy1 min readmarketwatch.com
- Latest data from Cambridge’s Sarepta bodes well for FDA approval of Duchenne drugbizjournals.com
How To Predict The Next Sarepta (FDA Approval Stock) And Win BigForbes- Sarepta gains after-hours as FDA accepts application for Duchenne drug approvalbizjournals.com
- MAquestive shares jump on FDA approvalmarketwatch.com
- MAlnylam shares jump on FDA approvalmarketwatch.com
- MSarepta Therapeutics shares jump on news of critic’s departure from FDAmarketwatch.com
- Shares of Sarepta soar after hours on plans to submit drug approval applicationbizjournals.com
- MSarepta Therapeutics shares tank as hopes for new drug approval fademarketwatch.com